All News
Medication adherence is a problem
Much has been written about tapering medications in rheumatic diseases, often due to high costs of medications, a desire to avoid side effects and patient preference to take less medications (especially if they have side effects).
This is countered by something we all know: medications not taken don’t work, and those that are frequently missed may not provide optimal outcomes for the majority of patients.
Arora @BichileT et al. PJP prophylaxis practice among nephrologists and rheumatologists @RheumNow #ACR22 Abstr#1282 https://t.co/3VyJR6k76U https://t.co/VM5rnbmv9h
Richard Conway RichardPAConway ( View Tweet)
We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/iUY4azQQyD
Dr. John Cush RheumNow ( View Tweet)
Raadsen et al. RA-specific CV risk specifically targets pre-existing atherosclerotic vessels. So if no baseline CVD, traditional risk factors are main driver rather than RA. Risk without prevalent CVD (HR 1.16 95%CI 0.88 –1.53) @RheumNow #ACR22 Abstr#1408 https://t.co/1Y6WeEFmim https://t.co/qG3RMNnbqt
Richard Conway RichardPAConway ( View Tweet)
Michailidou et al. PMR has increased neutrophil activation and NET formation. Elevated calprotectin. Immune complexes assoc neutrophil activation. Neutrophil activation inhibited by FcγRIIA blockade @RheumNow #ACR22 Abstr#1545 https://t.co/EAqZ3byMoP https://t.co/T2PmIExSKj
Richard Conway RichardPAConway ( View Tweet)
Sarsam @sclerodermaUM et al. Long term follow up of abatacept in SSc (ASSET). @RheumNow #ACR22 Abstr#1521 https://t.co/BvWSSSIqN0 https://t.co/kc2HxjkVh8
Richard Conway RichardPAConway ( View Tweet)
Another poster from my research group!
Investigated recommendations in ACR/EULAR guidelines
<1/6th informed by head 2 head RCT
We need more comparative effectivness research!
#ACR22 @RheumNow #1284 https://t.co/HQoeKj0cxy
Mike Putman EBRheum ( View Tweet)
Moura et al. 22 case series of VEXAS. Lung involvement common, Symptoms in 95%. HRCT abnormal 73%. PFTs abnormal 20%. Changes non specific inflammatory parenchymal, steroid responsive. @RheumNow #ACR22 Abstr#1569 https://t.co/E6vUnvxSdQ https://t.co/l4aEmpy8OX
Richard Conway RichardPAConway ( View Tweet)
Fukui et al. Association different alcoholic drinks and urate in Japan. Patients always ask about this. We should drink more sake it seems! @RheumNow #ACR22 Abstr#1206 https://t.co/En5pSMUNp7 https://t.co/c67r9fsHJT
Richard Conway RichardPAConway ( View Tweet)
Exciting trial for PMR, SAPHYR RCT of sarilumab (IL6) in relapsing/refractory PMR
I interviewed Robert Speira aobut the trial for @RheumNow, arriving to your podcast inbox!
Overall very exciting, need options for this group and nice to see PMR getting attention
#ACR22 #ACRBest https://t.co/nPurVhpNws
Mike Putman EBRheum ( View Tweet)
Johnson et al. Increased risk of heart failure and heart failure mortality in RA. No improvement over time. @RheumNow #ACR22 Abstr#1204 https://t.co/MGEgmORGuL https://t.co/9zDYjZiCh1
Richard Conway RichardPAConway ( View Tweet)
Ferrada @maferradastrong et al. HSCT in VEXAS. 20 evaluated. Indications refractory disease or haematologic abnormalities. Completed in 2, ongoing in 2. @RheumNow #ACR22 Abstr#1568 https://t.co/01SeHQcIsh https://t.co/XCgz4cTQCJ
Richard Conway RichardPAConway ( View Tweet)
What to do? Should you cycle TNFi in PsA and SpA or move on? 86 Pts from CorEvitas w PsA or Ankylosing spondylitis. TNF switching was not a home run - at 6 mo on 2nd TNF only 15% were in low disease activity. 21% persistence at 2 yrs. Use another Rx! Abst#1499 #ACR22 @rheumnow
Janet Pope Janetbirdope ( View Tweet)
Inflammation causing HTN in AS?
Abstract #0384 #ACR22 @RheumNow
🫀413 patients followed for median 12 years
🫀14% developed HTN
🫀Baseline disease duration was an independent RF for HTN
🫀ESR > 20 sig. associated with HTN
Catherine Sims, MD DrCassySims ( View Tweet)
Martín-Varillas et al. ADA vs certolizumab in Cystoid Macular Edema in Behcets. "Equally" effective here but 80% of the certolizumab patients were previously refractory to ADA. @RheumNow #ACR22 Abstr#1567 https://t.co/ZKr38i2iA5 https://t.co/Jbtqlv9YAF
Richard Conway RichardPAConway ( View Tweet)
Kayadibi et al. Venous halo sign in Behcets. 86% of Behcets thrombophlebitis vs 13% non-Behcets @RheumNow #ACR22 Abstr#1251 https://t.co/fnSDYhaFa0 https://t.co/luIZH9SHwW
Richard Conway RichardPAConway ( View Tweet)
Ab1011 #ACR22
@SMerjanah: Fracture rates among vets with AS
Increasing fx incidence for AS and comparator groups over time
There was increase in fractures during TNFi era 2004-2021 compared to pre-TNFi, does not show fx sparing effect
@RheumNow https://t.co/fTSYbFcxqo
Eric Dein ericdeinmd ( View Tweet)
Wiebe et al. Steroids <=5mg/day not associated negative effect on BMD. Of course steroid-related increase in fracture risk is not fully captured by BMD effect @RheumNow #ACR22 Abstr#1318 https://t.co/Ond5gzopRa https://t.co/HX2AUyQmsf
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#1569 Lung complications are common in #VEXAS but what are the common radiologic findings? A cohort study in 22 men showed abnormalities were found in most patients but were non-specific. Most commonly parenchymal changes (73%) @RheumNow https://t.co/kjYSHON2yN
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Carter et al. Case series showing rapid effect of anifrolumab in refractory discoid lupus and SCLE. @RheumNow #ACR22 Abstr#0974 https://t.co/RjnNxjGJoP…
Richard Conway RichardPAConway ( View Tweet)